TW202333676A - 吡唑並〔3,4-d〕嘧啶化合物之固體形式 - Google Patents

吡唑並〔3,4-d〕嘧啶化合物之固體形式 Download PDF

Info

Publication number
TW202333676A
TW202333676A TW111148528A TW111148528A TW202333676A TW 202333676 A TW202333676 A TW 202333676A TW 111148528 A TW111148528 A TW 111148528A TW 111148528 A TW111148528 A TW 111148528A TW 202333676 A TW202333676 A TW 202333676A
Authority
TW
Taiwan
Prior art keywords
solid form
solid
temperature
radiation
ray powder
Prior art date
Application number
TW111148528A
Other languages
English (en)
Chinese (zh)
Inventor
卡羅琳 普魯克斯拉弗朗斯
約翰 阿梅迪歐二世
艾瑞卡 沃科瓦
Original Assignee
美商輝瑞股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商輝瑞股份有限公司 filed Critical 美商輝瑞股份有限公司
Publication of TW202333676A publication Critical patent/TW202333676A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW111148528A 2021-12-16 2022-12-16 吡唑並〔3,4-d〕嘧啶化合物之固體形式 TW202333676A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163290136P 2021-12-16 2021-12-16
US63/290,136 2021-12-16

Publications (1)

Publication Number Publication Date
TW202333676A true TW202333676A (zh) 2023-09-01

Family

ID=85172741

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111148528A TW202333676A (zh) 2021-12-16 2022-12-16 吡唑並〔3,4-d〕嘧啶化合物之固體形式

Country Status (11)

Country Link
US (2) US12012412B2 (cg-RX-API-DMAC10.html)
EP (1) EP4448529A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024546844A (cg-RX-API-DMAC10.html)
KR (1) KR20240119299A (cg-RX-API-DMAC10.html)
CN (1) CN118401525A (cg-RX-API-DMAC10.html)
AU (2) AU2022416644B2 (cg-RX-API-DMAC10.html)
CA (1) CA3242577A1 (cg-RX-API-DMAC10.html)
IL (1) IL313314A (cg-RX-API-DMAC10.html)
MX (1) MX2024007517A (cg-RX-API-DMAC10.html)
TW (1) TW202333676A (cg-RX-API-DMAC10.html)
WO (1) WO2023114995A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024546844A (ja) 2021-12-16 2024-12-26 ファイザー・インク ピラゾロ[3,4-d]ピリミジン化合物の固体形態
WO2025043067A2 (en) * 2023-08-22 2025-02-27 Cardurion Pharmaceuticals, Inc. Pyrazolo[3,4-d]pyrimidinone compounds for the treatment of chronic heart failure

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
CN109893653A (zh) * 2017-12-11 2019-06-18 王慧敏 Pde9抑制剂的新用途
JP2024546844A (ja) * 2021-12-16 2024-12-26 ファイザー・インク ピラゾロ[3,4-d]ピリミジン化合物の固体形態

Also Published As

Publication number Publication date
CA3242577A1 (en) 2023-06-22
US12012412B2 (en) 2024-06-18
US20240300961A1 (en) 2024-09-12
JP2024546844A (ja) 2024-12-26
IL313314A (en) 2024-08-01
CN118401525A (zh) 2024-07-26
KR20240119299A (ko) 2024-08-06
AU2025275149A1 (en) 2026-01-08
WO2023114995A1 (en) 2023-06-22
EP4448529A1 (en) 2024-10-23
AU2022416644B2 (en) 2025-09-11
AU2022416644A1 (en) 2024-07-04
MX2024007517A (es) 2024-08-19
NZ812114A (en) 2025-08-29
US20230192707A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
US6242460B1 (en) Zolpidem salt forms
US20240300961A1 (en) Solid forms of pyrazolo[3,4-d]pyrimidine compounds
CN107427503A (zh) 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
CA3230314A1 (en) Solid forms of bcl-2 inhibitors, method of preparation, and use thereof
US8993602B2 (en) Benzoic acid salt of otamixaban
JP2020073523A (ja) 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型
US12559478B2 (en) Co-crystal forms of selinexor
EA052651B1 (ru) ТВЕРДЫЕ ФОРМЫ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫХ СОЕДИНЕНИЙ
US11136332B2 (en) Morphic forms of marizomib and uses thereof
US10561667B2 (en) Orbit azine-fumarate, hydrate, crystal form and preparation method therefor
CN114127074A (zh) 无定形乌帕拉尼单甲苯磺酸盐
HK40112450A (en) Solid forms of pyrazolo[3,4-d]pyrimidine compounds
WO2000058310A1 (en) Zolpidem salts
TW201908320A (zh) 一種btk激酶抑制劑的結晶形式及製備方法
US20240368165A1 (en) Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
WO2026024591A1 (en) Tryptamine prodrug solid forms
HK40119275A (en) Co-crystal forms of a novobiocin analog and proline
WO2026011157A1 (en) Crystalline forms
HK40116055A (en) Novel sulfate salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist
CN116947891A (zh) 一种作为免疫调节剂的联苯类化合物的盐型、晶型及其制备方法
HK40038397B (en) Composition of fused tricyclic gamma-amino acid derivatives and the preparation thereof
WO2019070698A1 (en) Novel forms of ibrutinib
HK1234747B (en) Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound
KR20060073939A (ko) 비페프루녹스메실레이트(7-[4-([1,1'-비페닐]-3-일메틸)-1-피페라지닐]-2(3h)-벤즈옥사졸론 모노메탄설포네이트)의 안정한 결정질형태